Viking thinks the oral alternative offers a smooth transition from the subcutaneous form and might appeal to individuals ...

CEO Brian Lian highlighted 2024 as an exceptionally busy year, with successful results from four studies, including the Phase 2 VENTURE trial for subcutaneous VK2735, which demonstrated up to 14.7% ...

The excitement surrounding Viking Therapeutics (NASDAQ: VKTX) stock has been dying down significantly lately. In six months, the stock has lost more than 40% of its value. Many investors may have been ...

Stephanie Diaz; Investor Relations Manager; Viking Therapeutics Inc. Brian Lian; President, Chief Executive Officer, Director; Viking Therapeutics Inc. Greg Zante; C ...

Raymond James analyst Steven Seedhouse raised the firm’s price target on Viking Therapeutics (VKTX) to $125 from $122 and keeps a Strong Buy ...

Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial ...

Viking Therapeutics stock plunged early Thursday on an earnings report that included mostly incremental updates for its ...

Viking Therapeutics Inc (VKTX) reports significant R&D progress and financial bolstering despite increased losses and ...

Viking Therapeutics announces its fourth-quarter financial results after Wednesday's closing bell. Here's a look at the ...

Viking held cash, cash equivalents and short-term investments of $903M, compared to $362M as of December 31, 2023. 2024 ...

Shares of Viking Therapeutics (VKTX) slid 8% post-market after the biotech company issued its Q4 earnings report and a pipeline update. Read more here.